Toni Choueiri, MD (@DrChoueiri) / X

Toni Choueiri, MD

28K posts

Toni Choueiri, MD

@DrChoueiri

Chief GU Cancers @DanaFarber II Prof Medicine @HarvardMed II ⚽ lover II @PanMass 🚲rider.

Boston, MA

dana-farber.org/find-a-doctor/…

Joined January 2016

Pinned
Toni Choueiri, MD
@DrChoueiri
Jan 19
Dear Friends, Family, and Colleagues, I am honored and excited to share that I have registered for my 9th @PanMass as part of teammorecowbell.com. Each year, PMC gives all of us an opportunity to take action in the fight against cancer—a cause that defines my professional
17K
Toni Choueiri, MD
@DrChoueiri
Mar 28, 2020
#COVID19 course in 1 slide @OncoAlert
Toni Choueiri, MD
@DrChoueiri
Mar 19, 2020
In case you are wondering about IL-6 inhibitor Tociluzumab effect in #COVID19 serious infections: N=20. 19/20 discharged in 2 weeks. Improvement in lung lesions. Reduction in fever/C-reactive protein, increase O2 saturation among others. LINK to paper chinaxiv.org/abs/202003.000…
Toni Choueiri, MD
@DrChoueiri
Dec 29, 2022
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022: Some negative, some positive, but we learned from all! Feel free to add more & retweet & tag anyone involved This is not an exhaustive list! @OncoAlert @DanaFarber #OnwardFor2023
189K
Toni Choueiri, MD
@DrChoueiri
Jan 1, 2025
END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO
111K
Toni Choueiri, MD
@DrChoueiri
Jan 12, 2021
The paper that every cancer researcher saves, Cancer Statistics 2021 now published by @AmericanCancer. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…
Toni Choueiri, MD
@DrChoueiri
Oct 22, 2023
#Goosebumps #EV302 #ESMO23 Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦@tompowles1⁩ EV+Pembro irrespective…..WOW! 🤩
62K
Toni Choueiri, MD
@DrChoueiri
Apr 17, 2024
1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…
107K
Toni Choueiri, MD
@DrChoueiri
Feb 5, 2025
1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin
171K
Toni Choueiri, MD
@DrChoueiri
Sep 11, 2022
A waterfall plot or a tidal wave 🌊???? 🤩 😯 99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!! #ESMO22 ⁦@myESMO⁩ ⁦@MyriamChalabi⁩
Toni Choueiri, MD
@DrChoueiri
Dec 30, 2023
Now, the TOP 10 Clinical Trials in 2023. Not an exhaustive list. Many practice-changing and practice-informing trials! Feel free to add! @OncoAlert @TargetedOnc @OncLive @gotoPER @FDAOncology @OncBrothers
195K
Toni Choueiri, MD
@DrChoueiri
Nov 18, 2021
JUST IN: @US_FDA approves pembrolizumab for adjuvant treatment of RCC at intermediate-high/high risk of recurrence following nephrectomy, or following nephrectomy + resection of metastases. 1st adjuvant immunotherapy in RCC! fda.gov/drugs/resource… @DanaFarber @OncoAlert
Toni Choueiri, MD
@DrChoueiri
Dec 27, 2024
IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:
83K
Toni Choueiri, MD
@DrChoueiri
May 10, 2023
1/ Results from #COSMIC-313 are out @NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by @CharlesSwanton @AndresC27622123 #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…
148K